Immunogenic peptides

Abstract

The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic methods.

1 - 34 . (canceled) 
     
     
         35 . A nucleic acid encoding an immunogenic peptide having between 9 and 25 amino acids in length comprising at least 9 consecutive amino acids of the amino acid sequence of any one of SEQ ID Nos. 1 to 10. 
     
     
         36 . The nucleic acid of  claim 35 , wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID Nos. 11 to 20. 
     
     
         37 . An expression vector comprising a nucleic acid according to  claim 35 . 
     
     
         38 . A host cell or organism transformed or transfected with an expression vector according to  claim 37 . 
     
     
         39 . A vaccine or a pharmaceutical composition comprising the nucleic acid molecule of  claim 35 , an expression vector comprising the nucleic acid of  claim 35  or a host cell transformed or transfected with an expression vector comprising the nucleic acid of  claim 35 . 
     
     
         40 . A pharmaceutical composition according to  claim 39  and a pharmaceutically acceptable carrier or excipient. 
     
     
         41 . The nucleic acid of  claim 35 , wherein the immunogenic peptide is capable of stimulating a T-cell response. 
     
     
         42 . The nucleic acid of  claim 35 , wherein the immunogenic peptide is capable of producing a cytotoxic T lymphocyte (CTL) response. 
     
     
         43 . The nucleic acid of  claim 35 , wherein the immunogenic peptide is either 9 or 10 amino acids in length. 
     
     
         44 . The nucleic acid of  claim 35 , wherein the immunogenic peptide consists essentially of the amino acid sequence described in any one of SEQ ID Nos. 1 to 5. 
     
     
         45 . The nucleic acid of  claim 35 , wherein the peptide is capable of producing a T helper (TH) cell response. 
     
     
         46 . The nucleic acid of  claim 45 , wherein the peptide is from 18 to 24 amino acids in length. 
     
     
         47 . The nucleic acid of  claim 46 , wherein the peptide is 20 amino acids in length. 
     
     
         48 . The nucleic acid of  claim 45 , wherein the peptide consists essentially of the amino acid sequence of any one of SEQ ID Nos. 6 to 10. 
     
     
         49 . A pharmaceutical composition comprising two or more of the nucleic acid molecule of  claim 35 , an expression vector comprising the nucleic acid of  claim 35  or a host cell transformed or transfected with an expression vector comprising the nucleic acid of  claim 35  for simultaneous, sequential or separate administration. 
     
     
         50 . A method of treatment of cancer, comprising administering a therapeutically effective amount of the nucleic acid of  claim 35 , an expression vector comprising the nucleic acid of  claim 35  or a host cell transformed or transfected with an expression vector comprising the nucleic acid of  claim 35 , a vaccine comprising the nucleic acid of  claim 35 , an expression vector comprising the nucleic acid of  claim 35  or a host cell transformed or transfected with an expression vector comprising the nucleic acid of  claim 35 , or their combination to a patient in need thereof. 
     
     
         51 . The method of  claim 50 , wherein the cancer is either a haematologically derived malignancy selected from multiple myeloma, mantle cell lymphoma, Hodgkin's lymphoma, T-cell lymphomas, follicular lymphoma, Burkitt's lymphoma, T-cell rich B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and acute and chronic myeloid leukaemia, or a non-haematologically derived malignancy selected from brain, melanoma, lung, breast, gastric, kidney, prostate, testicular, ovarian, uterine, colorectal and liver cancers and adenocarcinoma of the colon.